Long-term Data Show Ra-223 Safe in Advanced Prostate Cancer – Medscape

See on Scoop.itProstate Cancer: Psycho-Social Aspects to Disease Pathway Management

Long-term Data Show Ra-223 Safe in Advanced Prostate Cancer Medscape In an updated report of the ALSYMPCA trial, no major safety issues were identified within ~1.5 years after the end of treatment in a population of men with castration-resistant…

Terry Hill‘s insight:

This is good news!

See on login.medscape.com